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Objectives We hypothesized that low-density lipoprotein (LDL) reduction regardless of mechanism would improve calf mus-
cle perfusion, energetics, or walking performance in peripheral arterial disease (PAD) as measured by magnetic
resonance imaging and magnetic resonance spectroscopy.
Background Statins improve cardiovascular outcome in PAD, and some studies suggest improved walking performance.
Methods Sixty-eight patients with mild to moderate symptomatic PAD (age 65  11 years; ankle-brachial index [ABI]
0.69  0.14) were studied at baseline and annually for 2 years after beginning simvastatin 40 mg (n  20) or
simvastatin 40 mg/ezetimibe 10 mg (n  18) if statin naïve, or ezetimibe 10 mg (n  30) if taking a statin.
Phosphocreatine recovery time was measured by 31P magnetic resonance spectroscopy immediately after
symptom-limited calf exercise on a 1.5-T scanner. Calf perfusion was measured using first-pass contrast-
enhanced magnetic resonance imaging with 0.1 mM/kg gadolinium at peak exercise. Gadolinium-enhanced
magnetic resonance angiography was graded. A 6-min walk and a standardized graded Skinner-Gardner exercise
treadmill test with peak VO2 were performed. A repeated-measures model compared changes over time.
Results LDL reduction from baseline to year 2 was greater in the simvastatin 40 mg/ezetimibe 10 mg group (116  42
mg/dl to 56  21 mg/dl) than in the simvastatin 40 mg group (129  40 mg/dl to 90  30 mg/dl, p  0.01).
LDL also decreased in the ezetimibe 10 mg group (102  28 mg/dl to 79  27 mg/dl, p  0.01). Despite this,
there was no difference in perfusion, metabolism, or exercise parameters between groups or over time. Resting
ABI did improve over time in the ezetimibe 10 mg group and the entire study group of patients.
Conclusions Despite effective LDL reduction in PAD, neither tissue perfusion, metabolism, nor exercise parameters improved,
although rest ABI did. Thus, LDL lowering does not improve calf muscle physiology or functional capacity in PAD.
(Comprehensive Magnetic Resonance of Peripheral Arterial Disease; NCT00587678) (J Am Coll Cardiol 2011;
58:1068–76) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.034Peripheral arterial disease (PAD) is an independent predic-
tor of cardiovascular disease morbidity and mortality (1) and
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2011, accepted April 19, 2011.is associated with a decrease in functional ability over time
(2). Accordingly, for patients with PAD, it is critical to
focus medical therapy on reducing their underlying cardio-
vascular risk as well as improving their functional status.
Despite great strides in medical progress for the treatment
of coronary artery disease, the therapeutic options and
corresponding evidence base remain limited in PAD (3).
See page 1077
Lipid-lowering therapy with 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (statins) in PAD reduces
all-cause and cardiac mortality (4), and the benefit is related
to both the dose of statin and degree of low-density
lipoprotein (LDL) lowering. As a result, it is recommended
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August 30, 2011:1068–76 Calf Muscle Perfusion and Energetics in PADthat patients with PAD (5) receive statins with a goal LDL
level of 100 mg/dl. Statins have been shown to improve
pain-free walking performance in patients with PAD (6);
however, the mechanisms remain unclear. Additional stud-
ies have failed to corroborate an improvement in functional
ability in patients with PAD treated with statins; however,
there was evidence of less decline in walking performance in
this group (7). Ezetimibe, a nonstatin drug, is effective in
lowering LDL cholesterol when added to statin therapy (8)
but is of uncertain value in PAD. Ezetimibe has been
studied in atherosclerotic plaque regression trials involving
carotid artery intimal medial thickness (9–11); however, it
has not previously been evaluated in a clinical trial in lower
extremity PAD.
Previous work by our group (12) used magnetic resonance
imaging (MRI) techniques to demonstrate the multiple
determinants of functional status in patients with PAD. We
found that abnormal mitochondrial function is independent
of calf muscle tissue perfusion; however, both correlate with
impaired exercise capacity in patients with PAD and symp-
tomatic claudication. Given the complexity of functional
capacity in PAD and the pleiotropic (noncholesterol low-
ering) effects of statins (13), including improved endothelial
function, stabilization of atherosclerotic plaque, and de-
creased vascular inflammation, they may have particular
therapeutic benefit in this disease. Our study of superficial
femoral artery plaque volume in this patient group demon-
strated plaque regression with new statin therapy with or
without ezetimibe, but progression when adding ezetimibe
to ongoing statin therapy, although there was no placebo for
the latter group (14). The potential benefits of LDL
lowering with statins and/or ezetimibe on the underlying
physiology in PAD remain incompletely understood.
Thus, we aimed to investigate the role of LDL lowering
on the following parameters in PAD patients: 1) calf muscle
perfusion with first-pass contrast-enhanced MRI; 2) calf
muscle energetics with measurement of phosphocreatine
(PCr) recovery time constant by 31P magnetic resonance
pectroscopy (MRS); 3) macrovascular disease measured
ith magnetic resonance angiography (MRA); and 4) ex-
rcise capacity with functional testing. Two parallel studies
ere performed with the same primary endpoints. In the
rst study, statin-naïve patients were randomized to receive
ither simvastatin or a combination of simvastatin plus
zetimibe. The second part of the study evaluated patients
lready taking a statin with LDL 80 mg/dl who received
pen-label ezetimibe in addition to ongoing statin therapy.
ethods
tudy design. Patients between the ages of 30 and 85 years
ith symptoms of intermittent claudication and an ankle-
rachial index (ABI) between 0.4 and 0.9, based on vascular
aboratory testing done during the screening period, were
ligible. Exclusion criteria included rest pain, critical limb
schemia, contraindication to MRI, pregnancy, and comor-idities that severely limited the
atient’s ability to perform a
alking treadmill test. Approxi-
ately 350 vascular laboratory
atients were screened for partic-
pation over the 15-month re-
ruitment period. Screened pa-
ients who did not enroll in the
tudy refused to participate due
o travel concerns, the extended
ature of the study, or antici-
ated difficulty with functional
esting due to musculoskeletal is-
ues or frailty. Patients provided
ritten informed consent before
tudy enrollment. The study pro-
ocol was approved by the Hu-
an Investigation Committee at
he University of Virginia. The
resent study was performed as a
re-specified secondary endpoint
n a study of atherosclerotic
laque regression.
In the randomized study,
tatin-naïve patients (no statin therapy for at least the
revious 6 months) regardless of baseline LDL cholesterol
nderwent a double-blind randomization to simvastatin 40
g (S group) or a combination pill of simvastatin 40 mg 
zetimibe 10 mg (S  E group) daily using a block
randomization scheme. For the parallel direct treatment
study, patients were enrolled already on statin therapy but
with LDL 80 mg/dl and had open-label ezetimibe 10
mg/day added (E group) to their usual statin. For the
randomized study, the investigators and study subjects were
blinded to therapy, and all results until follow-up studies
and data analysis were complete.
Study protocol. As previously described, the study was
divided over 2 days to allow sufficient time between exercise
portions of the protocol to avoid fatigue and ischemic
pre-conditioning. Patients were admitted overnight to the
General Clinical Research Center. Due to imaging time
constraints, only the more symptomatic leg was studied by
MRI/MRS. Patients returned at yearly intervals twice and
underwent repeat testing each year using the same
protocols.
Magnetic resonance protocols. MRI protocols were com-
pleted on an Avanto 1.5-T scanner and MRS protocols on
a Sonata 1.5-T scanner (both Siemens Healthcare, Erlan-
gen, Germany) because MRS hardware and software were
only available for the latter. Calf muscle perfusion was
immediately measured at peak plantar flexion exercise using
a magnetic resonance–compatible foot pedal ergometer at a
rate of 10 to 12 rpm with first-pass gadolinium-enhanced
imaging as previously described (15) (Fig. 1). Time-
intensity curves were generated with Argus software (Sie-
Abbreviations
and Acronyms
ABI  ankle-brachial index
E group  study group
treated with usual statin
and open-label ezetimibe
added
LDL  low-density
lipoprotein
MRA  magnetic
resonance angiography
MRI  magnetic resonance
imaging
MRS  magnetic
resonance spectroscopy
PAD  peripheral arterial
disease
PCr  phosphocreatine
S group  study group
treated with simvastatin
S  E group  study group
treated with simvastatin 
ezetimibemens Healthcare) for a region of interest in the calf muscle
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Calf Muscle Perfusion and Energetics in PAD August 30, 2011:1068–76with the greatest increase in signal intensity and the corre-
sponding input artery (typically the popliteal). Tissue per-
fusion index methodology was shown to differentiate PAD
from normal subjects. Likewise, PCr recovery kinetics by
31P MRS after peak plantar flexion exercise in the calf
muscle was shown to reproducibly discriminate PAD from
normal subjects (16). PCr recovery time constant was
calculated using a monoexponential fit of PCr concentration
versus time, immediately after peak exercise (Fig. 2). MRA
was performed with a moving table/bolus chase technique in
3 stations from the abdominal aorta to the foot after
administering gadopentetate dimeglumine (0.2 mmol/kg)–
enhanced MRA with grading by 2 experienced observers by
visual consensus using 2 different grading schemes, as
previously described (9) (Fig. 3). For reference, values from
normal subjects for the MRI measures are as follows:
Figure 1 Post-Exercise Calf Muscle Perfusion
First-pass contrast-enhanced calf muscle perfusion at baseline (A) and
year 1 (B) in the same patient in the study group treated with simvastatin 
ezetimibe. Increased signal intensity is seen in the anterior tibialis and soleus
muscles at both time points (perfusion index: A  0.37, B  0.52).
Figure 2 PCr Plots
Phosphocreatine (PCr) recovery time plots at baseline (A) and year 1 (B) in a pati
with respective PCr recovery time constants of 98 and 121 s.perfusion index  0.69  0.17 and PCr recovery time  34 
16 s. Normal values for the MRA parameters are assumed
(run off resistance index  4 and MRA index  0).
Functional measures. Subjects performed measures of ex-
ercise performance until symptom-limited claudication, ex-
haustion, or completion of study protocol: a 6-min walk and
a standardized graded Skinner-Gardner exercise treadmill
test (17) as previously described. Total treadmill exercise
time, symptom-limited VO2, and pre-/post-exercise ABI
were measured during the treadmill test, as previously
described. The time spent in physical activity at different
intensities was assessed using the Aerobic Center Longitu-
dinal Study’s Physical Activity Questionnaire (18). The
questionnaire was administered using an interview tech-
nique to increase accuracy (19). Total physical activity was
calculated as MET·H·week1 (1 MET  3.5 ml·kg·min1),
using the Compendium of Physical Activities (20).
Lipids. Fasting lipids were measured at study entry and
annually for 2 years. Patients were screened at 8 weeks via
study coordinator verbal questioning and annually thereafter
for symptoms of muscle pain, weakness, or tenderness, and
blood was drawn for liver function tests at the same time
points.
Statistical analysis. Primary outcomes were LDL choles-
terol and change in perfusion index and PCr recovery time
constant over time. All other lipid measures, MRA param-
eters, and exercise performance were secondary outcomes.
All data and patient characteristics were presented as mean SD
for continuous variables and number (%) for categorical
variables. A p value 0.05 was considered statistically
significant. All statistical analyses were performed using
SAS version 9.1.3 (SAS Institute, Cary, North Carolina).
Comparisons of categorical variables between groups were
performed with the chi-square test. Linear repeated-
the study group treated with simvastatin  ezetimibeent in
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August 30, 2011:1068–76 Calf Muscle Perfusion and Energetics in PADmeasures models were used to estimate changes in MRI
parameters over time within each group and to compare
changes in MRI parameters between S and S  E groups.
he repeated-measures model includes all patients studied
t baseline except for those with interval revascularization
ho were excluded from analysis. All lipid and MRI
arameters are reported from the repeated-measures mod-
ls, with Bonferroni adjustment for pairwise comparisons.
ubjects with incomplete data were assumed to be missing
t random, and imputation was not used due to the patient
umbers. Due to skewness, log-transformation was used for
everal exercise and laboratory parameters for model fitting.
elationships between changes in lipid parameters and
unctional outcomes were examined using either a Pearson
r Spearman correlation coefficient.
esults
atients. Eighty-seven patients were initially enrolled, but
patients withdrew before completing baseline imaging due
o claustrophobia. Thus, 85 patients were evaluated at
aseline (S group, n  22; S  E group, n  22; E group,
 41), and 68 were included in the study analysis after
xcluding 17 patients with interval revascularization of the
tudy leg (S group, 3; S  E group, 4; E group, 10). An
additional 4 patients died (1 in the S group, 1 in the S  E
group, and 2 in the E group), and 1 received a pacemaker
before the year 2 study, but their data were included in the
final model. Other vascular events included interval revas-
cularization of the nonstudy leg (S group, 1; S  E, 2),
myocardial infarction (S  E group, 1; E group, 2), and
transient ischemic attack/stroke (S  E group, 2; E group, 2).
Patients with renal insufficiency (glomerular filtration rate,
Figure 3 Representative MRA Images
Contrast-enhanced magnetic resonance angiography (MRA) images at baseline (A)
simvastatin  ezetimibe showing improvement in the appearance of superficial fe45 ml/kg/min; n  6) did not receive gadolinium due toconcerns for nephrogenic systemic fibrosis that were raised
after study initiation and were excluded from the MRA and
perfusion portions of the study. The baseline patient char-
acteristics for all groups are presented in Table 1. Two patients
in the S group and 7 in S E group had been taking statins
previously for a mean of 65  50 days. The mean time to
the year 1 visit was 389  58 days and 373  74 days later
for year 2.
There was a low rate of study drug discontinuation. In the
S group, 1 patient discontinued the study drug at year 1 and
an additional patient reported study drug noncompliance at
year 2. In the S  E group, 1 patient discontinued taking
the study drug between years 1 and 2. In the E group,
atorvastatin was the most commonly used statin (n  16;
mean dose, 33 mg) followed by simvastatin (n  7; mean
dose, 50 mg), and 1 patient each was taking lovastatin 40
mg, pravastatin 80 mg, and rosuvastatin 5 mg. Four patients
in the E group were unable to tolerate continuing statin use
due to nonspecific complaints; 1 additional patient self-
discontinued taking the statin at year 1, as did another at
year 2. All data were analyzed as intention-to-treat. Other
lipid-lowering agents were used by a few study subjects and
included niacin (S group, 1; E group, 2), fibrates (S  E
group, 2; E group, 1), and fish oil (S group, 1; S  E group, 1;
E group, 4).
Laboratory results. All groups had significant decreases in
LDL and total cholesterol from baseline to year 1, which
were sustained at year 2 (Table 2). The baseline LDL was
similar in the S E and S groups (116 42 mg/dl and 129
40 mg/dl, respectively). The year 1 LDL was less in the S
E group than in the S group (59  23 mg/dl and 96  34
mg/dl, respectively, p  0.01), and the difference was
ear 1 (B) from a patient in the study group treated with
artery stenosis (arrows) over time (MRA index: A  0.44, B  0.38).and y
moralsustained at year 2 (56  21 mg/dl and 90  30 mg/dl,
 study
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Calf Muscle Perfusion and Energetics in PAD August 30, 2011:1068–76respectively, p  0.01). There was no change in high-
density lipoprotein or triglycerides over the study period for
any group. In the E group, LDL decreased from baseline to
Patient Characteristics at Enrollment AccordingTable 1 Patient Characteristics at Enrollme
Characteristic
All Patie
(N  68
Age, yrs 65 1
ABI 0.69 0
Body mass index, kg/m2 29 6
Male 38 (56
Previous lower extremity revascularization 12 (18
Leg of interest 9 (13
Race
White 49 (72
Black 15 (22
Native American 4 (6)
Risk factors
Tobacco use 30 (44
Diabetes mellitus 22 (32
Hypertension 58 (85
History of CAD 42 (62
Hypercholesterolemia 50 (73
Medications
Aspirin/clopidogrel 47 (69
ACE inhibitor 31 (46
ARB 9 (13
Beta-blocker 29 (43
Cilastazol 8 (12
Values are mean  SD or n (%). There were no differences in any dem
ABI ankle-brachial index; ACE angiotensin-converting enzyme; ARB
group treated with usual statin and open-label ezetimibe added; S group
simvastatin  ezetimibe.
Lipid Parameters Over TimeTable 2 Lipid Parameters Over Time
Group Baseline Year 1 Year 2
Total cholesterol, mg/dl
S group 203 47 166 44* 157 35*
S  E group 189 44 129 30*† 123 26*
E group 171 35 138 33* 146 28*
All patients 184 43 143 37* 142 32*
LDL, mg/dl
S group 129 40 96 34* 90 30*
S  E group 116 42 59 23*† 56 21*†
E group 102 28 76 29* 79 27*
All patients 113 37 76 31* 75 29*
HDL, mg/dl
S group 44 14 45 13 44 14
S  E group 46 12 42 13 44 13
E group 42 12 41 12 43 12
All patients 44 12 43 12 44 13
Triglycerides, mg/dl
S group 175 118 139 87 125 71
S  E group 135 63 190 192 165 203
E group 149 72 130 52 152 70
All patients 152 84 153 120 152 116Values are mean  SD. *p  0.05 versus baseline. †p  0.01 versus S group.
HDL high-density lipoprotein; LDL low-density lipoprotein; other abbreviations as in Table 1.year 1 (102  28 mg/dl to 76  29 mg/dl, p  0.01) and
was stable at year 2 (79  27 mg/dl, p  0.01 vs. baseline).
MRI parameters. Change in perfusion index and PCr
recovery time constant were primary outcome measures
(Table 3). For the calf muscle perfusion index, there was no
difference between the S and S  E groups or change over
time for any group. There was no difference within groups
for PCr recovery time. For all patients, the PCr recovery
time remained unchanged between baseline (92  64 s),
year 1 (88  64 s), and year 2 (78  55 s, p  0.67 vs.
baseline). There was no change in the MRA runoff resis-
tance index between any group or in the study as a whole.
However, the MRA index was significantly higher in the S E
group than the S group at baseline and every subsequent
time point (Table 3). There was no statistically significant
change over time for any group or in the patients as a whole.
There was no correlation between the change in LDL on
calf muscle perfusion index or PCr recovery time constant.
Functional testing. Results are reported in Table 4. The
resting ABI was similar between the S and S  E groups at
baseline (0.71  0.23 and 0.65  0.24, respectively) and
year 1 (0.70  0.23 and 0.66  0.29, respectively). How-
ever, it was higher in the S group at year 2 (0.85  0.19)
than in the S  E group (0.66  0.12, p  0.03). The
resting ABI increased in the E group and in the study
population as a whole. In contrast, there was no change in
reatment Groupcording to Treatment Group
S Group
(n  20)
S  E Group
(n  18)
E Group
(n  30)
59 12 66 8 68 11
0.68 0.15 0.64 0.14 0.72 0.13
27 5 28 6 31 6
14 (70) 11 (61) 13 (43)
3 (15) 4 (22) 5 (17)
3 (15) 2 (11) 4 (13)
14 (70) 13 (72) 22 (73)
5 (25) 4 (22) 6 (20)
1 (5) 1 (6) 2 (7)
10 (50) 12 (67) 8 (27)
5 (25) 7 (39) 10 (33)
17 (85) 13 (72) 28 (93)
13 (65) 11 (61) 18 (60)
11 (55) 11 (61) 28 (93)
14 (70) 11 (61) 22 (73)
8 (40) 6 (33) 17 (57)
4 (20) 3 (17) 2 (7)
8 (40) 7 (39) 14 (47)
2 (10) 3 (17) 3 (10)
hic parameters in the S and S  E groups.
otensin receptor blocker; CAD coronary artery disease; E group study
group treated with simvastatin; S E group study group treated withto Tnt Ac
nts
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August 30, 2011:1068–76 Calf Muscle Perfusion and Energetics in PADchange in total treadmill exercise time or time to claudica-
tion (Table 4). Likewise, the 6-min walk for total distance
and onset of claudication were unchanged. There was no
correlation between the change in LDL with peak exercise
VO2 or 6-min walk parameters.
iscussion
his study used complementary MRI techniques and exer-
ise studies to comprehensively evaluate functional changes
n patients with PAD who were treated with lipid-lowering
herapy for 2 years. Statin-naïve patients randomized to
imvastatin or simvastatin  ezetimibe demonstrated no
hange in calf muscle perfusion or metabolism, and there
as no difference between groups in these MRI parameters
espite greater initial LDL lowering in the S  E group.
imilar findings were seen in the parallel study of patients
reviously on a statin with ezetimibe added at study enroll-
ent and when looking at the study population as a whole.
hus, effective LDL lowering did not improve lower ex-
remity functional capacity in PAD. However, resting ABI
id improve in the E group and in the patients as a whole,
hereas exercise ABI did not.
There is an increasing evidence base underlying the benefits
f statins on morbidity and mortality in PAD. In a study of
,374 patients with PAD, higher doses of statins were associ-
ted with lower incidence of all-cause mortality and cardiac
eath (4). Statin therapy reduced coronary events in elderly
atients with PAD and LDL 125 mg/dl (21). Analysis of
ata from the Scandinavian Simvastatin Survival Study dem-
Magnetic Resonance Parameters Over TimeTable 3 Magnetic Resonance Parameters Over Time
Group Baseline Year 1 Year 2
Perfusion index
S group 0.48 0.18 0.42 0.44 0.34 0.19
S  E group 0.42 0.13 0.44 0.23 0.37 0.13
E group 0.51 0.16 0.46 0.21 0.54 0.20
All patients 0.48 0.16 0.45 0.21 0.44 0.20
PCr recovery time constant, s
S group 94 77 85 80 84 68
S  E group 104 56 93 46 73 35
E group 83 62 86 65 74 58
All patients 92 64 88 64 78 55
MRA index
S group 0.73 0.50* 0.59 0.38* 0.71 0.46*
S  E group 1.10 0.72 1.26 0.73 1.32 0.86
E group 0.65 0.62 0.73 0.72 0.63 0.64
All patients 0.81 0.64 0.86 0.71 0.88 0.79
MRA ROR index
S group 15.4 7.2 13.7 7.9 13.9 6.2
S  E group 15.0 6.1 15.9 5.4 14.7 6.2
E group 11.2 5.8 11.3 6.4 9.5 4.4
All patients 13.5 6.5 13.6 6.5 12.7 6.2
Values are mean  SD. *p  0.05 versus S  E group.
MRA  magnetic resonance angiography; PCr  phosphocreatine; ROR  runoff resistance;
other abbreviations as in Table 1.nstrated a 38% reduction in the risk of the development ofew or worsening claudication symptoms over a follow-up
eriod of 5.4 years (22). In more than 6,700 patients in the
eart Protection Study, first major vascular events were re-
uced from 32.7% with placebo to 26.4% with simvastatin.
here also was a 16% relative reduction in the rate of first
eripheral vascular event, independent of baseline LDL, pri-
Exercise Parameters Over TimeTable 4 Exercise Parameters Over Time
Group Baseline Year 1 Year 2
Log (treadmill exercise time)
S group 6.08 0.84 5.90 0.93 5.92 1.08
S  E group 5.82 0.67 5.94 0.70 5.79 0.67
E group 5.94 0.78 5.89 1.04 5.78 0.63
All patients 5.95 0.76 5.92 0.91 5.82 0.77
Log (treadmill time to
claudication)
S group 5.2 0.8 4.9 0.8 5.0 0.9
S  E group 4.9 0.6 5.5 0.7 5.1 0.6
E group 5.2 0.9 5.5 0.7 5.2 0.6
All patients 5.1 0.8 5.3 0.7 5.1 0.7
6-min walk distance, ft
S group 1,103 407 1,189 388 1,078 485
S  E group 976 324 922 398 1,038 248
E group 1,007 435 1,057 460 1,099 394
All patients 1,024 397 1,036 434 1,075 374
6-min claudication distance, ft
S group 455 197 532 206 417 83
S  E group 448 187 413 185 461 161
E group 476 244 525 272 597 318
All patients 465 213 483 232 518 251
VO2, ml/kg/min
S group 14.6 4.6 12.8 3.7 14.8 4.6
S  E group 12.4 3.2 12.4 3.9 12.1 2.9
E group 12.1 3.8 11.6 3.8 12.3 4.6
All patients 12.8 4.0 12.2 3.7 12.9 4.2
Resting ABI
S group 0.71 0.23 0.70 0.23 0.85 0.19‡
S  E group 0.65 0.24 0.66 0.29 0.66 0.12
E group 0.77 0.23 0.79 0.24 0.85 0.26†
All patients 0.72 0.23 0.73 0.25 0.79 0.23*†
Post-exercise ABI
S group 0.53 0.23 0.54 0.23 0.51 0.22
S  E group 0.47 0.29 0.37 0.29 0.41 0.28
E group 0.51 0.31 0.53 0.25 0.61 0.39
All patients 0.51 0.28 0.48 0.26 0.52 0.33
Log (energy expenditure/week,
kcal)
S group 8.55 1.19 8.65 0.86 8.69 1.19
S  E group 8.72 1.61 8.49 1.03 8.19 1.66
E group 8.43 1.18 8.51 0.75 8.84 1.21
All patients 8.54 1.30 8.54 0.86 8.43 1.33
Log (metabolic hours
equivalent/wk)
S group 4.16 1.25 4.22 0.96 4.26 1.32
S  E group 4.20 1.50 4.06 0.89 3.75 1.47
E group 4.00 1.27 4.10 0.78 4.45 0.69
All patients 4.10 1.31 4.12 0.85 4.06 1.15
Values are mean  SD. *p  0.05 versus baseline. †p  0.05 versus year 1. ‡p  0.05 versus
S  E group.
Abbreviations as in Tables 1 and 2.
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cularization procedures (23). The latter study suggests that it
may be the pleiotropic effects of statins that are responsible for
benefit in PAD (24). In general, the mechanisms of benefit
remain incompletely understood (25). Despite guideline-
recommended use, statins are underused in the PAD popula-
tion (26).
Several studies suggest benefits of statins on walking perfor-
mance, although there is some lack of consensus in the
literature. A nonrandomized retrospective study demonstrated
that, when adjusted for comorbidities, patients with PAD and
an ABI 0.9 who were taking statins demonstrated better
-min walk performance, walking velocity, and overall perfor-
ance score. A similar patient group studied by the same
nvestigators showed less of a decline in annual walking
erformance when taking statins (27). Mohler et al. (6) studied
354 patients with symptomatic PAD randomized to either
placebo or atorvastatin 10 mg or atorvastatin 80 mg and found
an increase in pain-free walking time, a secondary endpoint,
after 12 months in the atorvastatin 80-mg group (p  0.025).
owever, the primary endpoints were negative. A recent
ulticenter double-blind trial found no increase in treadmill
alking time compared with dietary intervention alone after 28
eeks of lipid lowering with either high- or low-dose niacin
ovastatin (28). In addition, a randomized study of atorvastatin
0 mg for 6 months in PAD demonstrated no effect on
rachial artery flow-mediated dilation, carotid intimal-medial
hickness, or ABI (29).
Despite achieving significant LDL and total cholesterol
owering, no improvement in functional performance was
ound in the present study. There are several potential
xplanations for this. For one, nearly one-half of the study
opulation were already taking statins at the time of entry
nto the study and may have already received maximal
enefit. However, even the group of statin-naïve patients
id not show an improvement in exercise parameters. This
ay reflect a difference in power between studies, although
ohler et al. (6) likewise did not find an increase in
readmill walking time. Another potential explanation is
hat a decline in walking performance over time is expected
n PAD. A prospective cohort of PAD patients demon-
trated a decrease in 6-min walk distance over 2 years of
ollow-up (2). Thus, the absence of a functional decline or
ecrease in perfusion or energetics in the present study may
epresent a positive finding. Thus, a limitation of the
resent study is the absence of a placebo group without
ctive treatment to better understand the natural history.
ue to the known morbidity and mortality benefits with
tatins in PAD, a placebo group was not included in the
tatin-naïve patients.
An improvement in resting ABI was noted in the E
roup and the patient group as a whole. Although this is
ncouraging and underscores the simplicity and importance
f ABI as a measure, it is less clear as to why this benefit did
ot translate into any improvement in calf muscle physiol-
gy or exercise capacity. In our baseline study of this patient wopulation, we found a correlation between ABI and per-
usion index of r  0.33, p  0.01 (12). More subtle
easures of physiological changes are needed in this patient
opulation to test the potential benefits of novel therapies.
In the same patient population, we showed plaque re-
ression in the superficial femoral artery in statin-naïve
atients treated with either simvastatin or simvastatin/
zetimibe (14). It may be that this effect of the initiation of
tatin therapy is responsible for much of the therapeutic
enefit in PAD. Despite the plaque regression in the
tatin-naïve patients begun on statins, no improvement in
issue perfusion, cellular metabolism, or functional status
as seen. This suggests that the vascular benefits of statins
n PAD may primarily be at the level of macrovascular
therosclerotic plaque and not at the microvascular or
ellular level. It may be that improvement in tissue perfusion
nd cellular metabolism is necessary for improvement in
unctional performance. This speaks against the benefit of
ipid lowering in PAD being pleiotropic. This also points
ut the need for therapies focused on improving skeletal
uscle perfusion and metabolism in PAD.
In coronary artery disease, high-dose statin therapy has
een shown to reduce atherosclerotic plaque progression by
ntravascular ultrasound (30) and also to have an impact on
ngina and time to ischemic events (31). The mechanisms
f skeletal muscle dysfunction and claudication in PAD may
e quite different from those of myocardial dysfunction and
ngina in CAD.
tudy limitations. The study was primarily powered to
easure atherosclerotic plaque progression and not to detect
hanges in calf muscle perfusion or metabolism. As a result,
t was not powered to detect differences in perfusion or
etabolism among the groups. Given the relatively large
Ds for PCr recovery time, an improvement in calf muscle
nergetics over time with LDL reduction may have been
hown with a larger study population. It is possible that
ore than 2 years of statin therapy is needed to observe a
ifference in calf muscle perfusion or metabolism. Alterna-
ively, a more potent statin or higher dose of simvastatin
ay have resulted in an improvement in calf muscle
etabolism or perfusion. For example, an improvement in
ain-free walking time was found in PAD patients treated
ith atorvastatin 80 mg.
We studied only the more symptomatic leg for calf
uscle perfusion and energetics; however, the MRA and
xercise parameters are certainly influenced by disease in
oth legs. We did not measure the extent of collateral blood
essels seen on MRI because the development of a signifi-
ant collateral blood supply could alter the relationship
etween discrete stenosis seen on MRA and calf muscle
easures of perfusion or metabolism.
A significant number of patients (n  17) had to be
xcluded from study analysis due to interval revasculariza-
ion of their study leg, which reduced overall power of the
tudy. Due to the coexistence of renal disease in patients
ith PAD, additional patients were excluded from the
1075JACC Vol. 58, No. 10, 2011 West et al.
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concerns for nephrogenic systemic fibrosis. Nongadolinium-
based techniques for measuring calf muscle perfusion and
oxygenation are being developed. Arterial spin labeling (32)
and blood oxygen level–dependent imaging are 2 such
promising techniques (33).
Despite randomization of the statin-naïve patients, there
remained a significant difference in the MRA index at each
time point between S and S  E groups. Despite this
difference in macrovascular disease, no differences in base-
line physiological parameters were found. The relatively low
LDL cholesterol at baseline for the study population as a
whole may have contributed to the negative findings seen in
this study. There was no placebo control in the statin-naïve
patients for reasons stated previously. Without statins on
board, many of these parameters may have worsened over
the 2-year time period as has been demonstrated by others.
The study would have been strengthened by the use of a
placebo control in the E group.
Conclusions
In patients with peripheral arterial atherosclerosis, calf
muscle perfusion and metabolism did not improve with
lipid-lowering therapy despite a significant reduction in
LDL and total cholesterol. There was no decline in exercise
performance or MRI measurements of calf muscle perfusion
or metabolism, which might be construed as a positive
finding in PAD patients. However, the primary indication
for lipid-lowering therapy in PAD remains the reduction of
cardiovascular events and not specifically the improvement
of calf muscle physiology, energetics, or walking perfor-
mance. These findings point out the obvious need for
improved medical and alternative therapies to improve these
latter parameters as well as walking performance in these
patients.
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